

MEDICAID INFORMATION BULLETIN

Medicaid Information: 1-800-662-9651

medicaid.utah.gov

21-13 MULTI-FACTOR AUTHENTICATION FOR PRISM	1
21-14 PRESUMPTIVE ELIGIBILITY IS NOW PAPERLESS	1
21-15 UPDATES TO THE UTAH MEDICAID PROVIDER MANUAL FOR REHABILITATIVE MENTAL HEALTH AND SUBSTANCE USE DISORDER SERVICES	2
21-16 PHARMACY SERVICES UPDATES.....	2
21-17 RETROACTIVE PRIOR AUTHORIZATION DURING THE COVID-19 PUBLIC HEALTH EMERGENCY	5

21-13 Multi-Factor Authentication for PRISM

Multi-factor authentication is a method in which a user is granted access into a system using multiple factors: something the user knows (password) and something the user has (a token or code sent to a different device).

The Centers for Medicare & Medicaid Services (CMS) has recommended that Utah Medicaid implement multi-factor authentication for users accessing the PRISM application. This will be handled through UtahID. Providers will soon need to go through this multi-factor authentication process to access the PRISM application. Utah Medicaid will provide more information about this upcoming change in the April 2021 Quarterly MIB.

21-14 Presumptive Eligibility is Now Paperless

Effective February 1, 2021, all Presumptive Eligibility (PE) applications will be submitted through the online portal. This includes applications for Baby Your Baby (BYB) and Hospital Presumptive Eligibility (HPE). The PE online portal was launched in 2016. Eighty percent of providers already use it exclusively for all of their PE applications. The UDOH has worked with all PE providers to ensure they are prepared for this change.

This paperless process results in faster eligibility determinations, better application tracking, and ensures only trained, approved providers administer PE. If a PE provider submits a paper application to the eligibility agency, the agency will still determine Medicaid or CHIP eligibility, but the application will no longer be considered for PE.

The BYB online application can be found here <https://medicaid.utah.gov/byb-info>. HPE providers directly enter and determine PE eligibility for all HPE applicants.

If you have questions or comments, please email bybpolicy@utah.gov.

21-15 Updates to the Utah Medicaid Provider Manual for Rehabilitative Mental Health and Substance Use Disorder Services

In Chapter 1-5, Provider Qualifications, the first paragraph requires that supervision of licensed mental health therapists be provided in accordance with Title 58 of the Utah Code and the profession's practice act rule. Therefore, specific supervision requirements by type of license have been removed from Chapter 1-5, A.

Providers can access the revised provider manual at: <https://medicaid.utah.gov>

If you have questions or comments, please email Medicaidbh@utah.gov.

21-16 Pharmacy Services Updates

COVID-19 Vaccine Billing Guidance for Pharmacy POS Claims and Medical Claims

Utah Medicaid will reimburse an administration fee of \$22.67 when a COVID-19 vaccine is billed with the appropriate information via pharmacy point of sale or medical claims. Medical claims will use the vaccine code and the vaccine administration code listed in the table below. The coverage and reimbursement of COVID-19 vaccines and incentive amount will be billed as fee for service.

Pharmacies administering the vaccine to nursing home residents will be reimbursed the fee for vaccine administration when billed using provider type 60 (pharmacy).

COVID-19 vaccine Emergency Use Authorization covers administration of this vaccine for Medicaid members 16 years and older (Pfizer) and 18 years and older (Moderna). COVID-19 vaccines are not approved for members who are less than 16 years of age or members who are pregnant.

Vaccine Code	Vaccine Code Descriptor	Vaccine Administration Code(s)	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Minimum Dosing Interval
91300	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA/LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	0001A (1st dose) 0002A (2nd dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1000-1 59267-1000-01	21 days
91301	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA/LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	0011A (1st dose) 0012A (2nd dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	28 days

<https://www.ama-assn.org/system/files/2020-11/covid-19-immunizations-appendix-q-table.pdf>

Pharmacy Point of Sale Claims:

Billing for reimbursement of a free product (no associated cost) including an admin fee per NCPDP guidelines:

- The submitted Transaction Code (103-A3) is a "B1" (Claim Billing).
- The submitted Prescription/Service Reference Number Qualifier (455-EM) is a "1" (Rx Billing).
- The claim pricing segment follows the prescription claim request formula.
- The Product/Service ID (407-D7) should be submitted with the correct Product/Service ID Qualifier (436/E1) (in this example "03" (NDC))
- Product/Service ID (407-D7) contains the NDC Number of the vaccine or other product that was administered and obtained at zero cost.
- The Days' Supply (405-D5) should be submitted with a value of "1".
- The Quantity Dispensed (442-E7) should be submitted with the value that represents the quantity of drug product administered.
- The DUR/PPS Segment, with a "MA" (Medication Administered) in the Professional Service Code (440-E5), is submitted to identify the product was administered.
- The Incentive Amount Submitted (438-E3) is submitted to identify the pharmacy is seeking reimbursement for the administration of the product.
- The submission clarification code (420-DK)
 - Initial Dose(s): Submission Clarification Code of **2 "Other Override"** - defined as "Used when authorized by the payer in business cases not currently addressed by other SCC values to indicate the first dose of a multi-dose vaccine is being administered"
 - Final Dose: Submission Clarification Code of **6 "Starter Dose"** - defined as "The pharmacist is indicating that the previous medication was a starter dose and now additional medication is needed to continue treatment to indicate the second dose of a multi-dose vaccine is being administered"
- Utah Medicaid Incentive amount (administration fee) is as follows:
 - Single dose vaccine \$22.67
 - Vaccines requiring two or more doses

- Initial dose \$22.67
- Subsequent dose \$22.67
- Basis of Cost Determination (423-DN) should be submitted with the value “15” (Free product or no associated cost).

Medical Claims:

For guidance on how to bill for COVID-19 Vaccines and Administration visit:

<https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>

Prior Authorization Updates

The following Pharmacy Prior Authorization forms have been updated and can be found here:

<https://medicaid.utah.gov/pharmacy/prior-authorization/>

PA Form	Status	Effective Date	Information
Intravitreal Implant	Update	2/15/21	Includes Fluocinolone and Dexamethasone products
Botulinum Toxins	Update	2/15/21	Update to notes
Buprenorphine & Buprenorphine/Naloxone	Removed	2/1/21	Prior authorization has been removed

Oral Buprenorphine and Buprenorphine/Naloxone Products

Effective February 1, 2021, the following medications have been updated on the Preferred Drug List (PDL) and can be found here: <https://medicaid.utah.gov/pharmacy/preferred-drug-list/>

Preferred Products	Daily Dose Limit	Daily Quantity Limit
Buprenorphine tablet	24mg	3 sublingual tabs
Suboxone film	24mg	3 sublingual films
Non-Preferred Products	Daily Dose Limit	Daily Quantity Limit
Bunavail	12.6mg-2.1mg	2 buccal films
buprenorphine/naloxone	24mg	3 sublingual films/tabs
Zubsolv	17.1mg-4.2mg	2 sublingual tablets

21-17 Retroactive Prior Authorization During the COVID-19 Public Health Emergency

During the COVID-19 public health emergency, and due to potential changes in staffing patterns and capacity at Medicaid and with our community partners, all pharmacy and medically administered services are eligible for retroactive prior authorization in order to allow Medicaid providers to continue to provide services to Medicaid members without disruption. Services must meet Medicaid criteria for authorization and payment. During this time, providers will not be penalized for late submissions that are due to the COVID-19 public health emergency. Please continue to submit as timely as possible.